StockData
Cardinal Health Inc logo

Cardinal Health Inc (CAH) KPIs and segments

CAHNYSEWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends June 30
Số liệu tài chính tới Q4 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/3042% above fair value
$278.32−0.93 (-0.33%)

Close on Nov 18, 2026Market cap $64.73BP/E 38.5Yield 0.73%

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của Cardinal Health · năm tài chính kết thúc ngày 30 tháng 6

Nhìn nhanh KPI của Cardinal Health: 33 chỉ số vận hành, trong đó có Other Growth Businesses Revenue, Pharmaceutical & Specialty Solutions Reported Revenue và Global Medical Products & Distribution Segment Profit, lấy từ 216 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Năm tài chính của Cardinal Health kết thúc ngày 30 tháng 6 — Q1 FY27 = CQ3 2026 (quý dương lịch).

Periods

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q1 FY27
Q4 FY26
Q3 FY26
Q2 FY26
Q1 FY26
Q4 FY25
Q3 FY25
Q2 FY25
Q1 FY25
Q4 FY24
Q3 FY24
Q2 FY24
Pharmaceutical and Specialty Solutions($M)
58,84856,11160,66959,20555,37250,43350,84947,99055,60750,62253,202
GMPD($M)
3,1283,1483,2593,1843,1993,1603,1543,1233,1093,1133,127
Other Operating Segment($M)
1,7211,7061,7241,6411,6091,3041,2831,1861,1721,1541,135
Kỳ báo cáo trước đây (báo cáo lần cuối 2023)2
United States($M)
63,26960,54265,21763,61159,74654,49854,85851,89159,44854,46457,049
Non-US($M)
428423435419434399428408440425415
Pharmaceutical and Specialty Solutions($M)
645784687667535662531530482582495
Other Operating Segment($M)
183179179166160134118104111110106
GMPD($M)
1502537467039188472211
Kỳ báo cáo trước đây (báo cáo lần cuối 2023)2
Pharmaceutical and Specialty Solutions($M)
1,4021,5161,4261,3481,1991,2661,0991,081
GMPD($M)
703543539551591526530519
Other Operating Segment($M)
457438433420414329314302
Other Operating Segment($M)
-48-25-23-15-36-18-22-12
GMPD($M)
-60-32-23-19-61-28-21-23
Pharmaceutical and Specialty Solutions($M)
-68-37-23-32-62-33-12-11
Pharmaceutical and Specialty Solutions($M)
40,77741,03243,40538,68337,31335,73432,12529,21529,14930,496
GMPD($M)
6,6516,8886,9937,1336,8897,2017,0557,1487,0477,357
Other Operating Segment($M)
4,0984,0654,0734,0494,0452,7262,7202,6112,6062,692
Kỳ báo cáo trước đây (báo cáo lần cuối 2023)2
Other Growth Businesses Revenue ($M)($M)5
1,7641,7211,7061,7241,6411,6091,3041,2831,1861,1721,1541,135
at-Home Solutions Revenue ($M)($M)
1,1461,1081,1281,1851,1151,089817835739733730739
Nuclear and Precision Health Solutions (NPHS) Revenue ($M)($M)
505497478440436430403372373363352330
OptiFreight Logistics Revenue ($M)($M)
113116100999090847674767266
Other Growth Businesses Reported Revenue Growth YoY (%)(%)
7.0%7.0%31.0%34.0%38.0%37.0%13.0%13.0%13.0%15.0%14.0%11.0%
Other Growth Businesses Segment Profit ($M)($M)3
193183179179166160134118104111110106
Other Growth Businesses Segment Profit Margin (%)(%)
10.9%10.6%10.5%10.4%10.1%9.9%10.3%9.2%8.8%9.5%9.5%9.3%
Other Growth Businesses Margin Change YoY (bps)(bps)
8282211181352175-14-36
Other Growth Businesses Reported Profit Growth YoY (%)(%)
16.0%14.0%34.0%52.0%60.0%44.0%22.0%11.0%8.0%11.0%9.0%10.0%
Pharmaceutical & Specialty Solutions Reported Revenue Growth YoY (%)(%)5
6.0%6.0%11.0%19.0%23.0%0.0%0.0%-4.0%-5.0%13.0%9.0%12.0%
GLP-1 Medications Revenue Growth Contribution (Percentage Points)(%)
5.0%5.0%6.0%
IRA WAC Price Reductions Revenue Growth Impact (Percentage Points)(%)
-4.0%-5.0%-6.0%
Pharmaceutical & Specialty Solutions Reported Profit Growth YoY (%)(%)
17.0%21.0%18.0%29.0%26.0%11.0%14.0%7.0%16.0%8.0%0.0%10.0%
Pharmaceutical & Specialty Solutions Margin Change YoY (bps)(bps)
12999314161120
The Specialty Alliance Physician MSO Common Unit Repurchases ($M)($M)
41856161900
Global Medical Products & Distribution (GMPD) Segment Profit Margin (%)(%)2
1.0%4.8%0.8%1.1%1.4%2.2%1.2%0.6%0.3%1.5%0.7%0.4%
GMPD Segment Profit Margin Change YoY (bps)(bps)
-4196-4457118335222-14
GMPD Reported Segment Profit Growth YoY (%)(%)
-28.0%91.0%-36.0%106.0%47.0%77.0%
Pharmaceutical and Specialty Solutions — Segment Revenue ($M)($M)7
62,58258,84856,11160,66959,20555,37250,43350,84947,99055,60750,62253,202
Pharmaceutical & Specialty — Cost of Products Sold ($M)($M)
61,00157,44654,59559,24357,85754,17349,16749,75046,909
Pharmaceutical & Specialty — Segment SG&A Expenses ($M)($M)
798757732739681664604568551
Pharmaceutical & Specialty — Total Segment Expenses ($M)($M)
61,79958,20355,32759,98258,53854,83749,77150,31847,460
Pharmaceutical & Specialty — Segment Profit Margin (%)(%)
1.3%1.1%1.4%1.1%1.1%1.0%1.3%1.0%1.1%0.9%1.2%0.9%
Pharmaceutical & Specialty — Segment Goodwill ($M)($M)
9,7299,6959,6689,8617,9667,9437,7364,3183,5553,5553,618
Pharmaceutical & Specialty — Segment D&A ($M)($M)
606270646168444627
Pharmaceutical & Specialty — Segment Additions to PP&E ($M)($M)
456837233262331211
Global Medical Products and Distribution (GMPD) — Segment Revenue ($M)($M)6
3,1903,1283,1483,2593,1843,1993,1603,1543,1233,1093,1133,127
GMPD — Cost of Products Sold ($M)($M)
2,6362,4252,6052,7202,6332,6082,6342,6242,604
GMPD — Segment SG&A Expenses ($M)($M)
521553518502505521487512511
GMPD — Total Segment Expenses ($M)($M)
3,1572,9783,1233,2223,1383,1293,1213,1363,115
GMPD — Segment Goodwill ($M)($M)
00000000000
GMPD — Segment D&A ($M)($M)
565554555547566049
GMPD — Segment Additions to PP&E ($M)($M)
166032231961282123
Other Segment (NPHS, at-Home & OptiFreight) — Total Segment Expenses ($M)($M)5
1,5711,5381,5271,5451,4751,4491,1701,1651,082
Other Segment — Cost of Products Sold ($M)($M)
1,3031,2641,2681,2911,2211,195975969884
Other Segment — Segment SG&A Expenses ($M)($M)
268274259254254254195196198
Other Segment — Segment Goodwill ($M)($M)
1,8141,7471,7471,7481,7451,7481,1701,1701,1701,1701,170
Other Segment — Segment D&A ($M)($M)
2827263029-1314018
Other Segment — Segment Additions to PP&E ($M)($M)
204825231536182212
Total Reportable Segments Profit ($M)($M)7
1,009978988903879765835667642640714612
Total Segment Cost of Products Sold ($M)($M)
64,94061,13558,46863,25461,71157,97652,77653,34350,397
Total Segment SG&A Expenses ($M)($M)
1,5871,5841,5091,4951,4401,4391,2861,2761,260
Total Segment Expenses ($M)($M)
66,52762,71959,97764,74963,15159,41554,06254,61951,657
Corporate Inter-Segment Revenue Elimination ($M)($M)
-23-25-25-25-21-21-19-22-22-21-21-22
Corporate Unallocated Assets ($M)($M)
5,9845,7734,7043,6125,3634,8754,2105,1024,0856,3195,3355,738
Corporate Unallocated D&A ($M)($M)
1039798858895764688
Corporate Additions to PP&E ($M)($M)
768853624273474444
United States Revenue ($M)($M)2
67,11363,26960,54265,21763,61159,74654,49854,85851,89159,44854,46457,049
United States Property and Equipment, Net ($M)($M)
2,5792,6072,4942,4452,3962,4222,106
International Property and Equipment, Net ($M)($M)
420424434432435436423
Legacy Pharmaceutical Segment Revenue (Pre-Q3 FY24 Structure, $M)($M)1
53,520
Legacy Medical Segment Revenue (Pre-Q3 FY24 Structure, $M)($M)1
3,928
Non-GAAP Operating Earnings ($M)($M)13
1,001935956877857719807635625605667585
Non-GAAP Operating Earnings Growth YoY (%)(%)
17.0%30.0%18.0%38.0%37.0%19.0%21.0%9.0%12.0%14.0%5.0%17.0%
Non-GAAP Gross Margin ($M)($M)
2,5962,5602,4982,3982,3182,2032,1221,9411,9021,8821,9351,854
Non-GAAP SG&A Expenses ($M)($M)
1,5951,6251,5421,5201,4611,4841,3151,3061,2771,2771,2691,269
Non-GAAP Pre-Tax Earnings ($M)($M)
934882840799788676741597598595640592
Non-GAAP Net Earnings Attributable to Cardinal Health ($M)($M)
759682750624611501568468460450511464
Non-GAAP Effective Tax Rate (%)(%)
18.5%22.5%10.2%21.4%21.9%26.3%22.4%21.4%23.0%24.6%19.9%21.4%
Non-GAAP Diluted EPS ($)($)
3.262.913.172.632.552.082.351.931.881.842.091.89
Non-GAAP Diluted EPS Growth YoY (%)(%)
28.0%40.0%35.0%36.0%36.0%13.0%13.0%2.0%9.0%29.0%14.0%31.0%
Pre-Tax Adjustment: Amortization & Other Acquisition-Related Costs ($M)($M)1
18212111413010413315210574778063
Pre-Tax Adjustment: Acquisition-Related Cash & Share-Based Compensation ($M)($M)1
9444112676410620
Pre-Tax Adjustment: Restructuring & Employee Severance ($M)($M)1
23402521202728924695328
Pre-Tax Adjustment: Impairments & (Gain)/Loss on Disposal of Assets ($M)($M)1
-44185-14233-173-18841
Pre-Tax Adjustment: Litigation (Recoveries)/Charges, Net ($M)($M)1
-47-311-180-9-105-31-405080-11
Non-GAAP Adjusted Free Cash Flow ($M)($M)1
1,5831,4461,6975431,2851,3042,799-250-1,3611,8191071,038
Cash Payments Related to Litigation Matters, Net ($M)($M)
338015-18404-31245376-70246-27
Full-Year Non-GAAP Diluted EPS Guidance — Low ($)($)22
12.8012.4010.7010.159.659.308.057.857.75
Full-Year Non-GAAP Diluted EPS Guidance — High ($)($)
1312.6010.8010.359.859.508.1587.90
Full-Year Non-GAAP Adjusted FCF Guidance — Low ($B)(M)
3.503.503.30332.751.5011
Full-Year Non-GAAP Adjusted FCF Guidance — High ($B)(M)
443.703.503.503.251.501.501.50
Pharma & Specialty Profit Growth Guidance — Low (%)(%)
10.0%8.0%22.0%20.0%16.0%11.0%11.5%10.0%4.0%
Pharma & Specialty Profit Growth Guidance — High (%)(%)
12.0%11.0%23.0%22.0%19.0%13.0%12.5%12.0%6.0%
GMPD Revenue Growth Guidance — Low (%)(%)
2.0%2.0%1.0%1.0%2.0%2.0%2.0%2.0%2.0%
GMPD Revenue Growth Guidance — High (%)(%)
4.0%4.0%3.0%3.0%4.0%4.0%4.0%4.0%4.0%
GMPD Segment Profit Guidance — Low ($M)($M)
200200150150
GMPD Segment Profit Guidance — High ($M)($M)
220220150150
Other (Growth Businesses) Revenue Growth Guidance — Low (%)(%)
12.0%11.0%26.0%26.0%26.0%26.0%17.0%10.0%10.0%
Other (Growth Businesses) Revenue Growth Guidance — High (%)(%)
14.0%13.0%28.0%28.0%28.0%28.0%19.0%12.0%12.0%
Other (Growth Businesses) Profit Growth Guidance — Low (%)(%)
17.0%15.0%36.0%33.0%29.0%25.0%16.0%10.0%10.0%
Other (Growth Businesses) Profit Growth Guidance — High (%)(%)
20.0%18.0%38.0%35.0%31.0%27.0%18.0%10.0%10.0%
Full-Year Capital Expenditures Guidance — Low ($M)($M)
700700600600600600500500500
Full-Year Capital Expenditures Guidance — High ($M)($M)
700700650650650600550550550
Full-Year Share Repurchases Guidance ($M)($M)
1,0001,0001,000750750750750750750
Full-Year Net Interest & Other Guidance — Low ($M)($M)
240240340325325275200200140
Full-Year Net Interest & Other Guidance — High ($M)($M)
290290340325325275215230170
Full-Year Non-GAAP Effective Tax Rate Guidance — Low (%)(%)
18.5%19.0%19.0%21.0%22.0%22.0%23.0%23.0%23.0%
Full-Year Non-GAAP Effective Tax Rate Guidance — High (%)(%)
19.5%20.0%19.0%23.0%24.0%24.0%23.5%24.0%24.0%
Full-Year Diluted Shares Guidance — Low (M)(M)
231233237237238238242243243
Full-Year Diluted Shares Guidance — High (M)(M)
232233237238238240242243243
Total Accrued Opioid Litigation Settlement Liability ($M)($M)2
3,9004,3004,3004,3004,3004,9004,9004,9005,0005,4005,3005,470
Current Portion of Opioid Settlement Liability ($M)($M)
197468477477486628636636789643438420
Accrued Restructuring Reserve Balance ($M)($M)
455573767179827594977039
Remaining Share Repurchase Authorization ($M)($M)3
5,8931,3931,7931,9932,4432,7432,7433,1183,1933,4933,493
Total Common Shares Repurchased (Shares)
2,158,6851,960,633928,4762,318,7072,025,433202,979,261670,4812,737,035419314
Common Shares Repurchased Under Publicly Announced Programs (Shares)
2,158,5821,960,591928,4192,318,6882,025,3852,979,191670,1192,735,978
Weighted-Average Price Paid per Share Repurchased ($)($)
232185215184148147126112110102107
Federal Prime Contract Obligations to Cardinal Health ($M)($M)4
000000000000
Department of Defense (DoD / Defense Logistics Agency) Obligations ($M)($M)
34.612110584.613192.693.393.514410511594.4
Department of Veterans Affairs (VA) Obligations ($M)($M)
6.309.207.9019.4928.754.335.966.270.454.131.6
Department of Health and Human Services (HHS) Obligations ($M)($M)
0.200.200.100.300.30-15.9-0.100.40-0.1010.100.60
Department of Justice (DOJ) Obligations ($M)($M)
0000000-00
McKesson Corporation (MCK) — Consolidated Revenue ($M)($M)3
110,957105,38096,295106,158103,15097,82790,82395,29493,65179,28376,35580,898
McKesson (MCK) — GAAP Operating Income/(Loss) ($M)($M)
1,6041,3192,1501,6191,4071,0361,5911,2245781,0291,216642
McKesson (MCK) — GAAP Net Income/(Loss) ($M)($M)
1,2186141,6821,1861,1107841,260879241915791589
McKesson (MCK) — Merchandise Inventories, Net ($M)($M)
28,21726,25924,20727,06726,13425,06523,00123,83724,17625,57121,13922,020
Cencora, Inc. (COR) — Consolidated Revenue ($M)($M)3
84,75578,35685,93283,72980,66475,45481,48779,05074,24168,41472,253
Cencora (COR) — GAAP Operating Income ($M)($M)
1,1201,14376018.58681,036706127673553823
Cencora (COR) — GAAP Net Income ($M)($M)
7641,641560-3406877184893.40484421602
Cencora (COR) — Merchandise Inventories ($M)($M)
21,03020,01024,07920,49320,13818,96620,50818,99918,30217,63118,652
Option Care Health, Inc. (OPCH) — Consolidated Revenue ($M)($M)3
1,4941,4421,3511,4651,4351,4161,3331,3461,2791,2271,1461,124
Accendra Health, Inc. (formerly Owens & Minor, OMI) — Revenue ($M)($M)3
6026136287096976826746956876602,613-5,125
Consolidated Revenue ($M)($M)13
67,51363,67260,94065,62764,00960,15954,87855,26452,27759,86754,86857,442
Consolidated Cost of Products Sold ($M)($M)
64,91761,11258,44263,23061,69057,95752,75553,32350,37557,98552,93355,588
Consolidated Gross Profit ($M)($M)
2,5962,5602,4982,3972,3192,2022,1231,9411,9021,8821,9351,854
Consolidated Distribution, Selling, General & Administrative Expenses ($M)($M)
1,5951,6251,5421,5041,4611,4841,3151,3061,2771,2771,2691,268
GAAP Restructuring and Employee Severance ($M)($M)
23402521202728924695328
GAAP Litigation (Recoveries)/Charges, Net ($M)($M)
473-1118091053140-50-8011
Consolidated GAAP Operating Earnings/(Loss) ($M)($M)
753729509707668428730549568401369505
Interest Expense, Net ($M)($M)
73791018880747435329283
Earnings/(Loss) Before Income Taxes ($M)($M)
688554392630598384665511541391342512
Provision for/(Benefit from) Income Taxes ($M)($M)
1321541215914414115711012415880143
GAAP Net Earnings/(Loss) Attributable to Cardinal Health ($M)($M)
554398399467450239506400416235261368
GAAP Diluted EPS Attributable to Cardinal Health ($)($)
2.381.701.691.971.8812.101.651.700.961.071.50
Diluted Weighted-Average Common Shares (M)(M)
233236237239241243245245246
Cash Dividends Declared per Common Share ($)($)
0.520.510.510.510.510.500.510.510.510.500.500.50
Total Assets ($M)($M)7
59,54457,29956,68958,08355,22853,12249,87147,00243,05945,12145,88046,573
Net Cash Provided by Operating Activities ($M)($M)5
1,3981,6921,8236869731,5202,920-396-1,6472,082-271,179

5 chỉ số không có số liệu trong 12 quý gần nhất — .

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • Cardinal Health, Inc. reports on a fiscal year ending June 30 (Q1: Jul–Sep, Q2: Oct–Dec, Q3: Jan–Mar, Q4: Apr–Jun); latest reported period is Q1 FY27 (ended September 30, 2026) and latest completed fiscal year is FY2026 (ended June 30, 2026).
  • Effective Q3 FY2024, Cardinal Health reorganized its operating structure into three reportable categories: Pharmaceutical and Specialty Solutions, Global Medical Products and Distribution (GMPD), and Other (comprising three high-margin growth operating segments: at-Home Solutions, Nuclear and Precision Health Solutions, and OptiFreight Logistics). Historical pre-reorganization Pharmaceutical and Medical segment series are preserved separately through Q2 FY24.
  • Only directly published point figures and cumulative year-to-date period splits (`quarter = year-to-date − previous year-to-date` and `Q4 = full year (10-K) − nine months (10-Q)` on cash flow and cumulative footnote schedules) are included; no self-computed ratios, margins, or growth rates are added. Consolidated-minus-standalone parent subtraction is not applicable because Cardinal Health, Inc. files consolidated U.S. GAAP financial statements as a holding parent without standalone parent operating revenue.
  • Peer SEC XBRL quarterly series for McKesson (MCK, March 31 FYE), Cencora (COR, September 30 FYE), Option Care Health (OPCH, December 31 FYE), and Accendra Health / Owens & Minor (OMI, December 31 FYE) are aligned by calendar quarter-end dates to Cardinal Health's fiscal quarters for apple-to-apple comparison.

Không hiện vì thiếu các kỳ gần đây (10)

  • Core Growth Businesses › at-Home Solutions Patient Count — Disclosed only as an approximate lower bound ('over 3 million patients' / 'more than 3 million patients annually') in Form 10-K and Investor Day materials
  • Core Growth Businesses › Solaris Health & Specialty Alliance MSO Provider & Site Counts — Disclosed as bounds ('more than 750 providers across more than 250 practice locations') or single-point transaction announcements ('~3,000 providers in 32 states') without a continuous multi-period series
  • Core Growth Businesses › Nuclear & Precision Health Solutions Pipeline & Clinical Trials — Disclosed as bounds ('more than 70 pipeline products', 'more than 15 Actinium-225 clinical trials') or single-quarter rollout targets ('130 radiopharmacies targeted by end of FY27')
  • Core Growth Businesses › ContinuCare Pathway Retail Pharmacy Network — Disclosed only as single-point bounds ('over 11,000 retail and grocery pharmacies', 'nearly 1,400 Publix pharmacies') in January 2026 conference update
  • Core Growth Businesses › U.S. Distribution & Manufacturing Facility Counts — Form 10-K Item 2 qualitative text ('one national logistics center and a number of primary pharmaceutical and specialty distribution facilities') does not report exact annual facility counts
  • Guidance Tracker › GMPD FY26 Segment Profit Guidance in Q4 FY25 & Q1 FY26 — Expressed only as a lower bound ('$140M+') prior to Q2 FY26 point/range disclosures
  • Governance › Board & Committee Average Attendance Rate (%) — Disclosed in the 2025 Proxy Statement only as a lower bound ('Exceeded 96% overall average attendance')
  • Environmental & Sustainability › Corporate Sustainability Report PDFs (cardinalhealth.com) — Corporate marketing CDN (www.cardinalhealth.com/content/dam) blocks automated connections via Akamai Bot Manager tarpit
  • Segment Economics, ASU 2023-07 Cost Structure & Geographic Footprint › Total Reportable Segments Profit ($M) › Total Reportable Segments Revenue ($M) — Discontinued or insufficient consecutive latest periods
  • Customer/Supplier Concentration, Opioid Liabilities, Working Capital, Leases & Governance › Share of Merchandise Inventories Valued Under LIFO Method (%) › Unrecognized LIFO Inventory Excess Over Average Cost ($M) — Discontinued or insufficient consecutive latest periods

Dữ liệu cập nhật 2026-11-07.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Cardinal Health

See a number that looks wrong?